These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 25264277)
1. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition. Lupino E; Ramondetti C; Buccinnà B; Piccinini M Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277 [TBL] [Abstract][Full Text] [Related]
3. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972 [TBL] [Abstract][Full Text] [Related]
4. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738 [TBL] [Abstract][Full Text] [Related]
5. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040 [TBL] [Abstract][Full Text] [Related]
6. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859 [TBL] [Abstract][Full Text] [Related]
7. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
8. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066 [TBL] [Abstract][Full Text] [Related]
9. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654 [TBL] [Abstract][Full Text] [Related]